Summary A case-control study was designed to identify associations between polymorphisms at p53, cytochrome P-450 (CYPlAl) and glutathione-S-transferases and endometrial cancer susceptibility. Among all polymorphisms analysed, an insertional variant in p53 (P53PIN3) and two polymorphisms in the 3'-end and exon 7 of CYPlAl showed significant association with enhanced endometrial cancer risk.
factors. The present study was therefore undertaken to examine p53, GSTM1, GSTTI1 and CYPlAI polymorphisms as potential molecular markers of endometrial carcinoma susceptibility.
MATERIALS AND METHODS
We analysed DNA (Esteller et al, 1995) . The 16-bp insertion in intron 3 of p53 (p53PIN3 allele) and GSTM1 and GSTT1 null genotypes was determined by polymerase chain reaction (PCR) (Lazar et al, 1993; Zhong et al, 1993; Pemble et al, 1994) . Genotyping of the p53 codon 72 and CYPlAl 3'-end and exon 7 (isoleucineto valine substitution in residue 462) polymorphisms was detected using PCR and restriction fragment length polymorphism (RFLP) (De La Calle-Martin et al, 1990; Hayashi et al, 1991; Shields et al, 1993) .
The odds ratio (OR) ard 95% confidence intervals (CIs) were calculated as a measure of the association between genotypes and endometrial cancer. The StatXact-Turbo statistical package was used to obtain exact P-values.
RESULTS
The Genetic susceptibility to endometrial cancer 1387 A representative PCR analysis for GSTM 1 genotyping is shown in Figure 1 . On the other hand, the GSTT1 null genotype in the endometrial carcinoma group was not statistically significant when compared with the control group (P = 0.74).
Finally, a statistically significant association was found between endometrial carcinoma and both CYPlAl polymorphisms studied (P = 0.02). The OR and 95% CI of endometrial cancer risk for the combined genotypes of heterozygous and homozygous rare mutant alleles at the 3'-end and exon 7 of the CYPlAl gene was the same: 3.67 . No significant differences were found in the distribution of both CYPlAI rare mutant alleles by histological type. The MspI and NcoI RFLP analysis for CYPlAl 3'-end and exon 7 polymorphisms is illustrated in Figure 2 .
DISCUSSION
Although endometrial carcinoma is a common female malignancy, little is known about genetic factors in the aetiology of the disease. Several studies have shown endometrial carcinoma to be a significant component in a dominantly inherited cancer syndrome, namely hereditary non-polyposis colorectal carcinoma; this involves mutations in DNA mismatch repair genes (Marra et al, 1995) . In addition, that mothers and sisters of endometrial cancer patients have been found to have 2.7 times the risk of endometrial cancer as control subjects (Schildkraut et al, 1989) .
To our knowledge, this is the first report of an association of p53 and CYPlAI genetic polymorphisms with endometrial cancer risk. In this study, we found an association between the presence of the p53PIN3 allele and endometrial cancer risk. A stronger significant association was found between endometrial carcinoma risk and two genetic polymorphisms in 3'-end and exon 7 of the CYPlAI gene. Finally, GSTM1 and GSTT1 null genotypes and p53 codon 72 polymorphism data were not significantly different in endometrial cancer patients and the control group.
Germline polymorphisms of the tumour-suppressor gene p53, such as the p53PIN3 allele, could be involved in endometrial cancer risk because p53 gene alterations have been widely described in endometrial tumours (Enomoto et al, 1993; Kihana et al, 1995) . In addition, the p53PIN3 allele has been previously reported as associated with a higher ovarian cancer risk (Runnebaum et al, 1995) , although other studies have not found this relation (Lancaster et al, 1995) . Adding internal consistency of our data, the frequencies for the p53PIN3 allele in our control population are similar to those described (Lancaster et al, 1995; Runnebaum et al, 1995) . Owing to the undetermined functional importance of the p53PIN3 allele and the few works reported, large cancer case-control studies and assessment of intrinsic p53 activity of the variant form are required.
Finally, our finding that two CYPlAI genetic polymorphisms are associated with endometrial cancer risk could be related to the involvement of oestrogens in the development of endometrial cancer. In premenopausal women, persistent anovulation, owing to the polycystic ovary syndrome (Nisker et al, 1978) and ovarian neoplasia, often causes an oestrogen-predominant milieu associated with the occurrence of endometrial cancers; in addition, adipose tissues contribute to the formation of extraglandular oestrogen (mainly oestrone), especially in perimenopause (Lippman and Swain, 1992) . Because oestrogen metabolism is partially determined by cytochrome P-450 activity under the control of CYPlAl and CYP1A2 genes, the polymorphisms studied may influence the production of oestrogen 2-hydroxylated metabolites (Schneider et al, 1984) and therefore individual susceptibility to endometrial cancer. In a parallel way, the individuals with rare CYPlAI genotypes could suffer alterations in the metabolism of polycyclic aromatic hydrocarbons (known human carcinogens widely distributed) to reactive mutagenic intermediates (Nebert, 1991) , perhaps also contributing to the higher endometrial cancer risk detected.
In conclusion, our preliminary data are consistent with a genetic susceptibility to endometrial cancer associated with the p53PIN3 allele and two rare CYPlAI genotypes. In addition to suggesting the contribution of polymorphisms in tumour-suppressor genes and carcinogen-metabolism genes to be an enhanced cancer risk, this study could provide a link with the epidemiological association between oestrogen exposure and endometrial cancer. Therefore, studies in larger populations of sporadic endometrial cancer cases, in families with endometrial cancer aggregation with different phenotypes, and in functional assessment of the genotypes described are in progress. ABBREVIATIONS GSTM1, glutathione-S-transferase mu; GSTTI, glutathione-Stransferase theta; CI, confidence interval; CYPlAI, cytochrome P-450 lAI; p53PIN3, p53 gene insertional polymorphism in intron 3; OR, odds ratio.
